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Heart failure (HF) is a public health concern with an im-
mense effect on the utilization of precious and finite health 
care resources. More than 23 million people worldwide 
have been affected by symptoms of HF (1). The equivocal 
criteria for diagnosing HF have led to variable projections 
of its true incidence, but its impact and frequency grant 
it the status of a modern-day epidemic (1). Its prevalence 
continues to follow an upward trend, as it parallels the eco-
nomic growth and progressive aging of a community. The 
syndrome of HF is multifaceted in origin, and encompasses 
a wide range of underlying clinical entities that all result in 
pronounced morbidity and mortality.
The changing demographic profiles of the present-day 
HF populations underscore the importance of pursuing a 
multidisciplinary approach that will vigilantly address not 
only the cardiac pathology, but also the numerous accom-
panying comorbidities. Mortality burden of heart failure is 
comparable to or greater than that of malignancies such as 
melanoma, breast, kidney, and colorectal cancers (2). Pro-
motion of campaigns that facilitate the perception of HF as 
an ominous disease should, therefore, be advocated.
The convergence of increasingly more effective acute HF 
therapies and the adverse downstream effects of modern-
day lifestyles will likely lead to a further increase in chronic 
HF patients.
In this issue of the Croatian Medical Journal, multiple venues 
of advanced HF treatment are reviewed (3-10). The issue in-
cludes scholarly articles portraying some of the fundamen-
tal facts pertaining to heart failure and its management, 
while also focusing on specific clinical problems.
Although heart transplantation has marginal epidemiolog-
ical gain, it remains the benchmark against which all other 
modes of management must be compared. The excellent 
10-year survival of heart transplantation recipients rein-
forces its position as the gold standard in the management 
of end-stage HF (11). While over the past decades substan-
tial advances in HF pharmacotherapy, biventricular pacing, 
and mechanical circulatory assistance have been made, 
the superiority of long term outcomes of heart transplan-
tation remains unchallenged. This issue of the CMJ contains 
a comprehensive report on pre-transplant and periopera-
tive predictors of heart transplantation outcomes (3). Mul-
tiple issues associated with organ transplantations such as 
immunosuppression, rejection, infections, and neoplastic 
disease act in concert to compromise the long-term out-
comes. Furthermore, cardiac allograft vasculopathy exerts 
an important impact on long term survival of transplant 
recipients. Its insidious and progressive nature warrants a 
comprehensive analysis, which was conducted in one of 
the articles in this issue (4)
The principal limitation of heart transplantation, howev-
er, stems from a continued lack of available organs. This 
discrepancy between limited donor availability and high 
organ demand provides a fertile ground for the imple-
mentation of implantable ventricular assist devices. High-
quality survival supremacy of mechanical circulatory as-
sistance over optimal medical therapy among patients 
with end-stage HF is juxtaposed to the high incidence of 
complications that accompany this technology (5). De-
vice-related infections, bleeding, and stroke are all poten-
tially catastrophic to the patient, and this is highlighted 
among LVAD recipients in whom a destination strategy is 
pursued. With only 30% of long-term LVAD recipients be-
ing free from any adverse event at 1 year post-implanta-
tion there is clearly room for improvement in both device 
design and postoperative management (12). Also, from 
a clinical standpoint, patient selection and timing of im-
plantation remain paramount.
Among many challenges that exert an important impact 
on outcomes in this patient population, clearly pivotal is 
the management of the failing right ventricle. Options 
for long-term support of the failing right ventricle 
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have not followed the rapid evolution seen in the LVAD 
arena. A common clinical scenario is unmasking of incipi-
ent right ventricular failure after LVAD implantation. Multi-
ple laboratory, clinical, and echocardiographic parameters 
have been employed in the effort to identify LVAD patients 
in whom right ventricular failure will occur, but an effective 
predictive system is still not available. Nonetheless, this is-
sue presents a summary of available scoring systems and 
their individual performances (6).
While the focus of the medical and industrial communi-
ties on long-term implantable devices is certainly warrant-
ed, one should also appreciate the progress made in the 
domain of supporting the circulation during acute cardiac 
failure (5,7,8). The modern heart failure specialist requires 
considerable expertise in navigating through the ever-ex-
panding portfolio of available devices. This issue of the CMJ 
provides a roadmap that aims to expedite this process.
The revolutionary paradigm shift from pulsatile to contin-
uous-flow ventricular assist devices allowed for their min-
iaturization, thereby rapidly expanding their clinical appli-
cability. Also, the benefits of this technology have been 
underscored by improved durability and a lower incidence 
of adverse events. The clear advantages of novel devices 
notwithstanding, adverse sequelae of long-term exposure 
to non-pulsatile blood flow have been identified. An arti-
cle in this issue (9) reviews the evidence on the link be-
tween non-pulsatile flow and several unfavorable clinical 
outcomes, such as adverse aortic valve remodeling, less ef-
ficient blood flow at the capillary level, and acquired von 
Willebrand’s syndrome.
Reducing the high thromboembolic burden associated 
with HF may become another therapeutic goal in this chal-
lenging patient population. The current evidence on anti-
thrombotic agents in HF patients, however, does not sup-
port their wider implementation (10).
In order to put the contemporary management strategies 
for advanced HF into perspective one has to contrast their 
unequivocal efficacy with their high financial and logistical 
burdens. Balancing these opposing forces requires finesse, 
and is pivotal to optimizing the results of HF management 
programs. Furthermore, equality of opportunity for all pa-
tients in the utilization of these finite resources should be 
fostered. The purpose of this theme issue is to disseminate 
information related to heart failure management, while 
providing insight into the associated challenges.
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